share_log

Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25

Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25

諾布爾資本市場以跑贏大盤的評級啓動對YS Biopharma Co的報道,宣佈目標股價爲5.25美元
Benzinga ·  2023/11/13 12:06

Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and announces Price Target of $5.25.

諾布爾資本市場分析師格雷戈裏·奧蘭德以跑贏大盤的評級開始對YS Biopharma Co(納斯達克股票代碼:YS)進行報道,並宣佈目標股價爲5.25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論